The RCTs included in our systematic review were not primarily designed to show an effect on CIMT, but on markers of endothelial dysfunction (flow-mediated dilation) (42), insulin sensitivity (steady-state glucose infusion rate/insulin) (43), or albuminuria (albumin-to-creatinine ratio) (45). This evidence concerns the gene ALB and endothelial dysfunction.